Since hormones exert their effects on cells by binding to specific receptors, the responsiveness of normal or neoplastic tissue to hormonal stimulation is at least partly determined by the presence and concentration of hormone receptors. A number of experimental tumours possess cell-membrane receptors for insulin (Capeau et al., 1978; Harmon & Hilf, 1976; Heuson et al., 1972; Pezzino et al., 1979) and the growth of some of these tumours is affected by changes in the ambient insulin concentration (Cohen & Hilf, 1975; Heuson et al., 1972) . Among human tumours, only breast cancer has been shown to possess insulin receptors (Holdaway & Friesen, 1977; Osborne et al., 1978) . A variety of cancers have here been studied by us in order to test the hypothesis that most, if not all, human cancers contain specific receptors for insulin.
Sixty-seven tissue samples were ob- (Holdaway & Friesen, 1977) of the method of Shiu & Friesen (Shiu et al., 1973) . In brief, tissue was homogenized in cold 0-3M sucrose with a polytron homogenizer and centrifuged at 15,000 g for 20 min at 4°C. The supernatant was centrifuged at 100,000 g for 60 min and the resulting pellet was resuspended in a volume of assay buffer (0-025M tris HCI, 10mM MgCl2, pH 7-6, 0-1% bovine serum albumin) estimated to give a final protein concentration of 3 mg/ml. This pellet is enriched in 5'-nucleotidase (Shiu & Friesen, 1974) and contains receptors for both prolactin and insulin (Holdaway & Friesen, 1977) . Protein concentration was measured by the Lowry method. The insulin-binding assay was performed using porcine insulin (24 u/mg) kindly -provided by Novo Industries (Copenhagen) and insulin was labelled with 1251 using chloramine-T (Freychet et al., 1971) . Membrane preparations (0-1 ml containing -0-3 mg protein) were incubated in duplicate with 1251-labelled insulin (0.2 ng) and increasing amounts of unlabelled insulin (0.5-5000 ng) in a total volume made up to 0-5 ml with assay Using these methods, significant insulin binding was detected in all tumour specimens except one breast-tumour sample which had a particularly low yield of membrane protein (1.5 mg/ml). In this specimen, specific binding was 1 8%. Scatchard analysis of binding of 1 251I insulin to different types of tumour is shown in Fig. 1 , and compared with insulin binding to normal placenta, fat and muscle. In 2 instances sufficient normal colon adjacent to a colon carcinoma was available for analysis of insulin binding.
Comparison of binding to tumour and normal adjacent tissue is shown in Fig. 2 were very similar in the normal and neoplastic tissue in both cases. Since insulin degradation by membranes may alter apparent binding (Kahn et al., 1974) (Fig. 2) . The rate of degradation of labelled insulin also appeared similar in 3 different types of tumour (colon, stomach, and breast).
Thus in this investigation we have found insulin-binding sites in membrane fractions prepared from a variety of different tumour types, including infiltrating ductal and colloid carcinoma of the breast, colonic adenocarcinoma, gastric carcinoma, adrenocortical carcinoma, lymphoma and phaeochromocytoma. Comparison of insulin binding in these tumours with normal insulin-responsive tissues reveals marked similarity in binding-site concentration and affinity (Table) . Scatchard plots were curvilinear both in tumours and normal tissues (Fig. 1) , indicating decreased affinity of binding with increasing receptor occupancy. This 62* effect appears to be common to insulin receptors in all normal insulin-responsive tissues, and has variously been ascribed to a single class of binding sites with site-tosite interactions (negative cooperativity) or to the presence of multiple classes of binding sites with decreasing affinity but increasing capacity (Rodbard, 1979) . The similar characteristics of insulin binding to normal and tumour tissue (Figs 1 & 2) suggest similar mechanisms operating to influence binding in neoplastic and nonneoplastic tissue. Although the specificity of the binding sites for insulin could not be tested in each tumour type because of the limited amount of tissue available, the specificity of these binding sites for insulin has previously been established in breastcancer membranes (Holdaway & Friesen, 1977) .
Insulin binding to colon carcinoma has characteristics remarkably similar to those in adjacent normal colon (Fig. 2) . Previous autoradiographic studies have shown that insulin binding in tumour tissue is not simply due to binding to normal tissue included in the tumour mass, and in the present study particular care was taken to exclude normal tissue from tumour samples. It thus appears that insulin receptors in normal cells are preserved during malignant transformation. This hypothesis would be consistent with observations in the Zajdela hepatoma (Capeau et al., 1978) and the R3230AC rodent mammary carcinoma (Harmon & Hilf, 1976) . In these experimental tumours, insulin receptors are identical (though in lower concentration) to receptors in the non-neoplastic host tissues. It has however also been shown that tumours may synthesize "ectopic" hormone receptors, such as the TSH receptor found in an adrenocortical carcinoma (Hinshaw & Ney, 1974) . In addition, there is evidence that there may be abnormal regulation of levels of "normal" insulin receptors in breast cancer (Benson & Holdaway, submitted for publication). Thus the synthesis and regulation of hormone receptors by tumour tissue may differ in several respects from nonneoplastic tissue. Although insulin binding was measured in the present studies in only 6 types of cancer, the finding of physiological concentrations of highaffinity binding sites for insulin in all but one tumour suggests that insulin binding is a common property of human cancer. Whether these binding sites are active in translating the biological signal of insulin remains to be determined. However, as insulin affects the growth rate of some experimental tumours (Cohen & Hilf, 1975; Heuson et al., 1972 ) the frequent occurrence of insulin-binding sites in human cancer suggests that insulin may help maintain or stimulate the growth of human tumours.
